ETF市场周报 | 指数走势出现分歧！创新药相关ETF估值修复持续

Market Overview - A-shares experienced steady growth in the first half of the week, followed by an overall adjustment in the latter half, with May CPI showing a month-on-month decline [1] - The three major indices had mixed performances, with the Shanghai Composite Index and Shenzhen Component Index down by 0.25% and 0.60% respectively, while the ChiNext Index rose by 0.22% [1] - Global uncertainty has led to increased interest in defensive assets, with high-dividend assets maintaining significant allocation value [1] ETF Performance - The top-performing ETFs this week included several related to innovative pharmaceuticals, with notable gains exceeding 10% for multiple funds [2] - Conversely, consumption and technology-related ETFs saw significant declines, with the top losers experiencing drops of over 4% [4][5] Investment Trends - China's share of global business development (BD) transactions has surged from 5% in 2021 to 42% by May 2025, indicating a growing international recognition of Chinese innovative pharmaceuticals [3] - Major transactions, such as the $60 billion collaboration between Heng Rui Medicine and Hercules, highlight the increasing trend of Chinese companies entering international markets [3] Fund Flows - The ETF market saw a net outflow of 43.36 billion yuan, with a notable preference for conservative investments, particularly in bond ETFs [6][8] - The top inflows were seen in bond ETFs, with the Credit Bond ETF leading with an inflow of over 30 billion yuan [8] Upcoming ETFs - Four new ETFs are set to launch next week, including the Changcheng CSI Dividend Low Volatility 100 ETF, which aims to provide a combination of high dividends and low volatility [10] - The Tianhong CSI A500 Enhanced Strategy ETF is also highlighted for its strong historical performance and potential for superior returns through active management [12]